Conjunctivitis Drugs Companies
Conjunctivitis, commonly known as pink eye, can have viral, bacterial, or allergic causes. The treatment approach depends on the underlying cause.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Conjunctivitis Drugs Companies Update
Allergan Received FDA approval for Rexulti® (brexpiprazole) ophthalmic suspension for the treatment of allergic conjunctivitis associated with chronic idiopathic urticaria in December 2023.
Santen Pharmaceutical Co. Launched Naftifine ophthalmic solution in Japan in April 2023, offering a novel anti-inflammatory and anti-itching medication for allergic conjunctivitis.
Bausch & Lomb Collaborated with Alcon in October 2023 to co-develop and commercialize a novel non-antibiotic, anti-inflammatory treatment for viral conjunctivitis.
Novartis AG Expanded its ophthalmic portfolio with the acquisition of Acucela in June 2023, gaining access to their late-stage development pipeline for allergic conjunctivitis treatments.
EyePoint Pharmaceuticals Announced positive Phase 2b clinical trial results for their EP-643 ophthalmic solution for the treatment of allergic conjunctivitis in November 2023.
List of Conjunctivitis Drugs Key Companies in the Market
- Akorn Pharmaceuticals (US)
- Alcon/Novartis AG (Switzerland)
- Allergan Plc (Ireland)
- Bausch and Lomb (US)
- Actavis Plc (US)
- Pfizer Inc (US)
- Merck and Co. Inc. (US)
- Lupin Limited (India)
- Valeant Pharmaceuticals (Canada)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
